This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dezentjé, V. O. Articles by Gelderblom, H. Search for Related Content PubMed PubMed Citation Articles by Dezentjé, V. O. Articles by Gelderblom, H. Related Collections Clinical Research Clinical Research: Response Markers and Mechanisms

Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer

Authors' Affiliations: Departments of ¹ Clinical Oncology, ² Clinical Pharmacy and Toxicology and ³ Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands

Requests for reprints: Hans Gelderblom, Department of Clinical Oncology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Phone: 31-0-71-526-3464; Fax: 31-0-71-5266760; E-mail: a.j.gelderblom{at}lumc.nl.

In October 2006 the Food and Drug Administration recommended an update in the tamoxifen label to reflect the increased risk of recurrence in breast cancer patients who are cytochrome P450 2D6 (CYP2D6) poor metabolizers. This recommendation was based on only a few studies at that time. More clinical studies addressing the relation between the CYP2D6 genotype and tamoxifen efficacy have been published since, mostly describing Caucasian populations in the adjuvant treatment setting. An updated analysis of the literature is presented. Furthermore, the possibility to implement CYP2D6 genotyping in clinical practice is evaluated by analyzing the results of six studies on mainly Caucasian patients using adjuvant tamoxifen. Three studies were consistent with the FDA advice, but the three other studies showed contradictory results. Although some of the published criticism on the negative studies is justified, this does not imply that these results should be discarded. The reviewed literature is put in perspective acknowledging the limiting effect of Mendelian randomization on confounding and the limitations of the various study designs. The current accumulation of data showing worse clinical outcome in patients with decreased CYP2D6 metabolism in other types of populations still indicates that the CYP2D6 genotype may well become a clinically relevant predictive marker. The CYP2D6 genotype might be one of the first predictors of therapeutic response in cancer care based on germline DNA creating the possibility to analyze blood instead of tumor.

This article has been cited by other articles:

				K. Brown Is tamoxifen a genotoxic carcinogen in women? Mutagenesis, June 7, 2009; (2009) gep022v1. [Abstract] [Full Text] [PDF]

				G. C. Prendergast Modeling Cancer Cell Signaling and Attacking It Cancer Reviews Online Content, February 1, 2009; 2009(2): 3 - 4. [Full Text] [PDF]

				H. J. Burstein and R. S. Punglia Optimizing Adjuvant Endocrine Therapy for Postmenopausal Women: Incorporating Decision Modeling Analysis ASCO Educational Book, January 1, 2009; 2009(1): 35 - 38. [Abstract] [Full Text] [PDF]